SEHK:2696
SEHK:2696Biotechs

A Look at Shanghai Henlius Biotech’s (SEHK:2696) Valuation Following Its Strategic Immunotherapy Partnership

Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline. See our latest analysis for Shanghai Henlius Biotech. Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total...
SEHK:2338
SEHK:2338Machinery

Weichai Power (SEHK:2338) Is Up 6.6% After Reporting Higher Nine-Month Sales and Earnings—What's Changed

Weichai Power Co., Ltd. reported earnings for the nine months ended September 30, 2025, posting sales of CNY 170.57 billion and net income of CNY 8.88 billion, both higher than the same period last year. The results showed an increase in both revenue and basic earnings per share from continuing operations, highlighting ongoing improvement in profitability and operational scale. With solid gains in sales and earnings, we'll examine how Weichai Power's consistent financial growth impacts its...
SEHK:2331
SEHK:2331Luxury

Li Ning (SEHK:2331): Assessing Valuation After Q3 2025 Earnings Call Spurs Investor Focus

Li Ning (SEHK:2331) just held its Q3 2025 earnings call, drawing focused attention from investors and analysts. These quarterly updates provide a revealing look at the company’s financial health and management’s outlook for the months ahead. See our latest analysis for Li Ning. Li Ning’s Q3 earnings call appears to have been a catalyst for movement, with the share price rising 1.75% on the day but pulling back 7.05% over the past week. While short-term volatility remains, the company’s total...
SEHK:9926
SEHK:9926Biotechs

Is Ivonescimab’s Phase III Success Transforming the Investment Case for Akeso (SEHK:9926)?

Summit Therapeutics recently announced that results from multiple Phase III trials of ivonescimab, a first-in-class bispecific antibody developed by Akeso for cancer treatment, were presented at major medical meetings and published in The Lancet, with strong positive findings for non-small cell lung cancer (NSCLC) patients in China. This clinical progress has already contributed to regulatory approval, imminent U.S. regulatory submission, and inclusion in China's National Reimbursement Drug...
SEHK:992
SEHK:992Tech

Is Lenovo a Bargain After AI Expansion Drives 16% Rally in 2025?

Ever wondered if Lenovo Group is truly a bargain, or if the market is missing something big? You are in the right place to dig into what is really driving value for this tech giant. Lenovo Group’s stock has been anything but flat, with a 16.0% year-to-date climb and an impressive 162.2% gain over the last five years, though it dipped -1.4% this week as the market recalibrated expectations. Global headlines have swirled around Lenovo's expansion in AI-powered devices and fresh investment in...
SEHK:66
SEHK:66Transportation

How MTR’s US$25 Billion Debt Programme May Shape Financial Flexibility for Investors (SEHK:66)

MTR Corporation Limited recently announced a US$25 billion debt issuance programme with an application for listing on the Hong Kong Stock Exchange, available for 12 months from October 31. This substantial planned capital raise highlights MTR's intent to secure funding for future development, operational support, or potential refinancing amid changing market conditions. We'll assess how this significant debt programme may influence MTR's future financial flexibility and reshape its long-term...
SEHK:2618
SEHK:2618Logistics

Will Southeast Asia Expansion and Deppon Updates Change JD Logistics' (SEHK:2618) Narrative?

JD Logistics recently announced that its board will convene on November 13, 2025, to review and approve unaudited results for the third quarter ended September 30, 2025, while its supply chain arm JoyLogistics introduced integrated delivery and installation services for bulky items in Malaysia and Singapore. This expansion into Southeast Asia, coupled with operational updates for its key subsidiary Deppon, draws attention to both growth opportunities and ongoing challenges for JD Logistics...
SEHK:579
SEHK:579Renewable Energy

Beijing Jingneng Clean Energy (SEHK:579): Expanding Margins Reinforce Investor Optimism Despite Slower Growth

Beijing Jingneng Clean Energy (SEHK:579) posted stable earnings, with average earnings growth of 6.5% per year over the past five years and net profit margins improving from 14.4% to 14.9%. Earnings growth for the most recent year came in at 5.8%, slightly below the company’s longer-term pace. Future earnings are forecast to increase 8.43% per year and revenue is expected to grow at 3.7% per year. Investors will likely focus on the company’s steady profit and revenue performance, as well as...
SEHK:1798
SEHK:1798Renewable Energy

Datang Renewable (SEHK:1798) Margin Compression Tempers Bullish Growth Narrative Despite 19% Earnings Forecast

China Datang Corporation Renewable Power (SEHK:1798) is guiding for earnings growth of about 19% annually, easily outpacing both the Hong Kong market’s 12% average and the expected 8.6% for market revenue. The company’s current net profit margin sits at 13.2%, a compression from last year’s 14.9%, while average annual earnings growth over the past five years has been 7.9%. With these numbers illustrating robust forward expectations but pointing to mixed margin dynamics, investors are...
SEHK:1368
SEHK:1368Luxury

Should Xtep International Holdings' (SEHK:1368) Convertible Bond Adjustment After Dividend Prompt a Closer Look From Investors?

Xtep International Holdings Limited recently adjusted the conversion prices of its 2021, 2024, and 2025 Convertible Bonds following the declaration and payment of its 2025 Interim Dividend, with these changes already put into effect. This move modifies the conversion terms for bondholders, which could affect future capital structure decisions and influence the investment preferences of existing and potential stakeholders. We will explore how the adjustment of convertible bond conversion...
SEHK:1277
SEHK:1277Oil and Gas

Kinetic Development Group (SEHK:1277) Valuation in Focus After Raising Stake in MC Mining

Kinetic Development Group (SEHK:1277) has raised its stake in MC Mining to over 40% by completing its share subscriptions. This move highlights its long-term commitment to the Makhado Project in South Africa. The company now plans to push its holding toward 51%, signaling ongoing interest in MC Mining’s future growth prospects. See our latest analysis for Kinetic Development Group. Kinetic’s ongoing investment push comes as share price momentum quietly builds, with a 1-month share price...
SEHK:1211
SEHK:1211Auto

BYD (SEHK:1211) Margin Compression Raises Fresh Doubts on Quality of Earnings Growth Narrative

BYD (SEHK:1211) reported five-year annualized earnings growth of 47.1%, while more recent annual growth sits at 13.1%. With earnings projected to climb 18.84% per year and revenue expected to increase by 12.4% annually, both outpacing Hong Kong market averages, investors are watching these growth metrics closely. Net profit margins came in at 4.6%, down a touch from last year’s 5%, reflecting ongoing pressure but leaving room for optimism about forward momentum. See our full analysis for...